Comera Life Sciences Holdings Inc

Comera Life Sciences Holdings, Inc. engages in developing medicines. It applies a deep knowledge of formulation science and technology to transform essential biologic medicines. The firm's approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen. The company was founded on January 31, 2022 and is headquartered in Woburn, MA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WOBURN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a proprietary drug-delivery technology to improve patient access, safety, and convenience, today announced the closing of a bridge financing with a syndicate of investors. Following the closing, the investors exercised a purchase option to acquire all of the outstanding common stock of the Company not already held by the investors to take the Company private. The financing and option exercise follows a robust effort by the Company, led by a Special Committee of the Company's Board of Directors, to explore strategic alternatives to maximize shareholder value.

Comera Life Sciences Announces Bridge Financing and Exercise of Take Private Option

WOBURN, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB: CMRA) (“Comera” or the “Company”), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has initiated a process to explore strategic alternatives to maximize shareholder value.

Comera Life Sciences Announces Process Exploring Strategic Alternatives

WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors.

Comera Life Sciences Appoints Dorothy Clarke to Board of Directors

– Final stage of technical evaluation near completion in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company –

Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights

WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today will present research demonstrating Comera's SQore™ platform capabilities in the development of subcutaneous monoclonal antibody formulations at the PODD: Partnerships in Drug Delivery conference in Boston, Mass.

Comera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery Conference

FG Financial Group Inc

Grove Collaborative Holdings

T Stamp

GEE Group

KULR Technology Group

FiscalNote Holdings Inc

Some of the most promising penny stocks can have multi-bagger potential over the long haul. After all, the combination of low prices, strong catalysts, and potentially high returns can be appealing.

These Are the ONLY 7 Penny Stocks to Consider in August 2023

Data published in the Journal of Pharmaceutical Sciences support further development of caffeine as a viscosity reducing agent for subcutaneous formulations of monoclonal antibodies

Comera Life Sciences Announces Publication of Study Reinforcing Caffeine's Viscosity Reducing Capabilities

– Advanced to final stage of technical evaluation in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company –

Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights

WOBURN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced a significant expansion of its SQore™ patent portfolio with the issuance of four new patents and two new notices of allowance. The six new patents, three issued in the United States and three covering Canada, Korea and India expand the number of proprietary viscosity reducing excipients in Comera's SQore platform and significantly broaden claims covered by previously issued patents.

Comera Life Sciences Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore™ Platform

– Ownership of proprietary sourcing for U.S.-manufactured lead SQore excipients allows for full control over supply chain and greater flexibility to support product development needs –

Comera Life Sciences Announces Collaboration with Quality Chemical Laboratories to Secure Proprietary Supply of SQore Excipients

– Significant progress in Comera's ongoing research collaboration with Regeneron, a leading U.S. biotechnology company –

Comera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business Highlights

WOBURN, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, today announced that its scientists and executives will participate in four upcoming scientific and industry conferences.

Comera Life Sciences to Participate in Four Upcoming Conferences

Notice of Allowance of U.S. patent application received for expansion of core viscosity reduction claims for excipients in SQore™ platform.

Comera Life Sciences Announces Expansion of Patent Portfolio Underlying Core Excipient Technology

– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company –

Comera Life Sciences Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

WOBURN, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, today announced it will present at the 22nd Annual PepTalk Conference, in San Diego on Wednesday, Jan. 18, 2023 at 5:15 p.m. PT. The conference will run from Monday, Jan. 16 through Friday, Jan. 20.

Comera Life Sciences to Present at 22nd Annual PepTalk Conference

WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that it has completed a private placement to existing stockholders, of 2,406,242 units, at a purchase price of $1.48 per unit, with each unit consisting of one share of the Company's common stock and one five-year warrant to purchase two shares of the Company's common stock at an exercise price of $1.23 per share, pursuant to the terms of a Securities Purchase Agreement entered into on January 2, 2023. Gross proceeds from the private placement of approximately $3.6 million are expected to be used for working capital and general corporate purposes.

Comera Life Sciences Closes $3.6 Million Private Placement Priced At-the-Market under Nasdaq Rules

WOBURN, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced it will be participating in the Benchmark Company's 11th Annual Discovery One-on-One Investor Conference to be held Thursday, December 1, 2022 at the New York Athletic Club in New York.

Comera Life Sciences to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Comera Life Sciences Reports Financial Results for Third Quarter 2022 and Business Highlights

WOBURN, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, today announced favorable results from its recently completed SEQURUS-2 study. Together with the SEQURUS-1 study, the preclinical results showed that Comera's caffeine-based SQore™ excipient did not result in local or systemic toxicity and had no impact on any measured pharmacokinetic (PK) parameters of ipilimumab when administered subcutaneously.

Comera Life Sciences Announces Favorable Preclinical Results of Lead SQore Excipient in SEQURUS-2 Study

Elected Officials, Industry Leaders Celebrate Biotech Workforce Growth at Ribbon-Cutting Event

Comera Life Sciences Expands Woburn Operations

Canoo

Reliance Global Group

Penny stocks to buy? That's what these insiders think.

3 Hot Penny Stocks To Buy According To Insiders In September

ADiTx Therapeutics

Kiora Pharmaceuticals

Here's what you need to know about buying penny stocks today The post Top Penny Stocks to Watch After the Market Crash appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Watch After the Market Crash

Shares of Comera Life Sciences (NASDAQ: CMRA ) are up by over 30% following a flurry of insider purchases. As the name suggests, Comera is a life sciences company that seeks to improve traditional intravenous injections through its SQore platform.

Insiders Are Buying Up Comera Life Sciences (CMRA) Stock. Here's Why.

WOBURN, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, today announced entry into a purchase agreement with Arena Business Solutions Global SPC II, Ltd. (“Arena”) for up to $15 million of the Company's common stock, with an option to increase by an additional $15 million to $30 million.

Comera Life Sciences Announces Up To $15 million Purchase Agreement with Arena Business Solutions

WOBURN, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today provided a business update and reported financial results for the quarter ended June 30, 2022.

News for Comera Life Sciences Holdings Inc Stock (CMRA)